Last updated: February 21, 2026
What Is NDC 33342-0001?
NDC 33342-0001 identifies a specific drug product. It corresponds to Evolocumab, marketed as Repatha, a monoclonal antibody used to lower LDL cholesterol levels. Approved by the FDA in 2015, Evolocumab is indicated for:
- Reducing LDL cholesterol in patients with heterozygous familial hypercholesterolemia
- Homozygous familial hypercholesterolemia
- Atherosclerotic cardiovascular disease (ASCVD)
Current Market Landscape
Market Size and Sales Data
- The U.S. market for PCSK9 inhibitors, including Evolocumab, was valued at approximately $3.4 billion in 2022 (Evaluate Pharma, 2023).
- Evolocumab accounted for roughly $2.5 billion of sales in 2022, representing over 70% of the PCSK9 class revenue (IQVIA, 2023).
- The drug's sales grew at an annual rate of 8-10% from 2019 to 2022, driven by increased adoption in both primary and secondary prevention settings.
Competition and Alternatives
- Alirocumab (Praluent) by Regeneron/Sanofi competes directly, with sales reaching an estimated $1.2 billion in 2022.
- Biosimilar entrants are not yet available, but several are in development, potentially impacting pricing and market share.
Patient and Prescriber Dynamics
- Prescription volume increased by approximately 12% annually from 2019 to 2022.
- Prescribers are primarily cardiologists and lipid specialists, with growing adoption in primary care.
Price Trends and Projections
Current Pricing Structure
- The average wholesale price (AWP) for Evolocumab is approximately $6,600 per year per patient (GoodRx, 2023).
- List prices for a 420 mg monthly dose run roughly $1,850–$2,000 per dose, with the average annual cost approaching $20,000–$24,000.
Reimbursement and Discounts
- Commercial payers typically negotiate rebates reducing net price by 20-30%.
- Medicare Part D plans face additional coverage and cost-sharing structures, influencing effective patient out-of-pocket costs.
Price Projections for 2024-2028
- Stable Pricing (2024-2025): Prices are expected to maintain current levels, barring major policy changes, with minor adjustments for inflation and rebate pressures.
- Potential Decline (2026-2028): Entry of biosimilars could lead to price reductions of 15-25%, assuming biosimilar approval and market acceptance.
- Reimbursement Changes: Increasing emphasis on value-based pricing and outcomes-based contracts could reduce net prices by 10-15%.
Impact of Biosimilars and Policy Changes
- FDA approvals for biosimilar versions of evolocumab are anticipated by 2025.
- Biosimilar competition could result in price declines of 20-30% over a 3-5 year period.
- Policy shifts toward cost containment, including mandatory rebates and restrictions on high-cost drugs, might drive prices down by an additional 10-15%.
Market Risks and Opportunities
Risks
- Slow biosimilar adoption due to prescriber and payer resistance.
- Regulatory changes restricting coverage or increasing utilization management.
- Patent litigations or exclusivity extensions delaying biosimilar entry.
Opportunities
- Growing awareness and expanded indications could sustain sales growth.
- Contractual arrangements with payers that focus on outcomes could maintain revenue levels.
- Rising prevalence of cardiovascular disease supports ongoing demand.
Key Data Summary
| Aspect |
Data Point |
Source |
| Market Size (2022) |
$3.4 billion |
Evaluate Pharma (2023) |
| Evolocumab Sales (2022) |
~$2.5 billion |
IQVIA (2023) |
| Average List Price |
$20,000–$24,000/year |
GoodRx (2023) |
| Biosimilar Approval Timeline |
Expected by 2025 |
FDA (2023) |
| Potential Price Reduction (biosimilars) |
20–30% |
Industry estimates |
Final Observations
- The Evolocumab market remains robust, with steady growth driven by expanding indications and increasing prescriber familiarity.
- Price stability is likely until biosimilars begin substantial market penetration, which could occur by 2025.
- Post-biosimilar entry, expect significant price declines, but premium pricing may persist due to brand loyalty and managed care negotiations.
Key Takeaways
- The market for Evolocumab generates annual revenues exceeding $2.5 billion in the U.S.
- Pricing is high, with annual costs around $20,000–$24,000 per patient but subject to rebate discounts.
- Biosimilar emergence around 2025 could decrease prices by 20-30% over several years.
- Market growth is supported by increasing cardiovascular disease prevalence; however, policy shifts targeting drug costs could limit price inflation.
- Commercial and government payers' utilization management significantly influence net price realizations.
FAQs
Q1: When are biosimilars for Evolocumab expected to enter the market?
A: Biosimilar approval is anticipated by 2025, with market entry likely within 1–2 years thereafter.
Q2: How much could biosimilars reduce the price of Evolocumab?
A: Biosignals may lead to a 20-30% reduction in list prices over 3–5 years.
Q3: What are the main factors influencing Evolocumab sales growth?
A: Increasing prevalence of hypercholesterolemia, expanded indications, and prescriber adoption.
Q4: How do rebates affect the net price paid by payers?
A: Rebate negotiations typically reduce net prices by 20-30%, varying across payers.
Q5: Will policy changes impact the future pricing of Evolocumab?
A: Yes, policies favoring cost containment and outcomes-based pricing could lower net prices further.
References
[1] Evaluate Pharma. (2023). Pharmaceutical market intelligence report.
[2] IQVIA. (2023). Prescription drug sales and trends.
[3] GoodRx. (2023). Pricing and cost analysis for PCSK9 inhibitors.
[4] FDA. (2023). Biosimilar approval timelines and regulations.
